Skip to main content

Table 1 Demographic and clinical characteristics of the study participants at baseline

From: The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson’s disease: a randomized, double-blind, double-dummy, parallel-group study

Characteristic Pramipexole ER Pramipexole IR Total
n=236 n=239 n=475
Age, mean (±SD) years 62.2(9.10) 61.8(9.03) 62.0(9.06)
  <65 140(59.8) 146(61.1) 286(60.5)
  ≥65 94(40.2) 93(38.9) 187(39.5)
Female sex, n (%) 80(34.2) 95(39.7) 175(37.0)
Body mass index, mean (±SD) kg/m 2 23.3(2.85) 23.3(3.06) 23.3(2.95)
Hoehn and Yahr stage, n (%)    
  On phase    
  2-3 226(96.6) 234(97.9) 460(97.3)
  4-5 8(3.4) 5(2.1) 13(2.7)
  Off phase    
  2-3 113(48.3) 119(49.8) 232(49.0)
  4-5 18(7.7) 18(7.5) 36(7.6)
  Missing 103(44.0) 102(42.7) 205(43.3)
UPDRS score, mean (±SD)    
  II 13.0(4.92) 13.0(5.97) 13.0(5.47)
  III 31.7(12.09) 32.1(12.78) 31.9(12.43)
  II+III 44.7(15.69) 45.1(17.31) 44.9(16.51)
PD stage, n (%)    
  Early 122(52.1) 133(55.6) 255(53.9)
  Advanced 112(47.9) 106(44.4) 218(46.1)
Duration of disease, mean (±SD) years 5.11(3.33) 4.82(3.09) 4.96(3.21)
  2 to <5, n (%) 146(62.4) 153(64.0) 299(63.2)
  ≥5, n (%) 88(37.6) 86(36.0) 174(36.8)
MMSE score, mean (±SD) 28.4(1.61) 28.4(1.44) 28.4(1.52)
ESS score, mean (±SD) 5.0(3.81) 5.4(4.13) 5.2(3.97)
  1. EES, Epworth sleepiness scale; MMSE, Mini Mental State Examination; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale.
  2. The chi-square test was used for categorical variables, and one-way analysis of variance for continuous variables. There were no significant between-group differences in any baseline characteristics.